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Abstract: Developing countries are hotspots for research and development of new drugs. In 
recent years, Western pharmaceutical companies have increasingly establish drug testing centers 
in countries such as India and Africa where the poor natives are in desperate need of medical 
care and the local doctors have started to rely on the high salaries paid to them for conducting 
clinical trials. If the clinical trials are conducted in the U.S., authorized government agencies 
monitor the activities taking place at domestic clinical trial centers. However, overseas clinical 
trials are monitored by the local government and have to follow less stringent regulations of the 
local countries. Although U.S. government officials can inspect these overseas testing centers, 
the inspections almost never take place because of insufficient funding for the inspections. This 
paper highlights the unethical treatment of research test subjects in developing countries and 
proposes that the FDA should be authorized to perform remove video surveillance of research 
testing centers in the U.S. as well as overseas.  
 
 2 
INTRODUCTION 
 
“There’s an app for that,” is the phrase used by the innovative smart phone application 
developers’ who advertise their new applications to the savvy smart-phone users. Borrowing 
from the same concept, it would be apt for the multi-million dollar pharmaceutical giants to 
boast, “there’s a pill for that.” From a simple common cold to more fatal diseases, there is a pill 
for all. Leaving behind the days when conniving charlatans took advantage of the naïve 
consumers by passing off low-grade and falsely-labeled products in the name of medicine, today, 
our society comprises of FDA regulated drugs, most of which go through a rigorous test in order 
to be determined safe for consumer use. Because these drugs need to be tested on human subjects 
before they are approved and sold in the marketplace, the demand of human test subjects has 
increased with the development and production of new drugs. However, it is not always easy to 
find a large number of test subjects in America because of well-publicized allegations of the 
failures of drug companies to warn patients of side effects associated with the drug.
1
 
   In contrast, pharmaceutical companies have an easier time recruiting human test subjects 
in foreign countries. For instance, India, a country that is nicknamed the “guinea pig of the 
world” offers a large number of clinical test subjects.2 This large turnout is because the 
volunteers who are poor, or in poor heath, are willing to gain access to healthcare by 
                                                        
1
 Yevgenia Shtilman, Pharmaceutical Drug Testing in the Former Soviet Union: Contract Research 
Organizations As Broker-Dealers in an Emerging Testing Ground for America's Big Pharma, 29 B.C. 
Third World L.J. 426 (2009) citing Marcia Angell, The Truth About the Drug Companies, N.Y. REV. OF 
BOOKS, July 15, 2004 at 52 
2
 Jennifer Kahn, India: A Nation of Guinea Pigs, Wired Magazine, Mar. 1, 2006, at 142 (the article 
describes India as “global hot spot” for foreign pharmaceutical companies' drug trials and also describes 
how poor Indians volunteer for clinical trials without any information about the adverse effects of the 
drug). 
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participating in risky trials.
3
 The average cost of recruiting patients is 40% of the trial’s budget, 
making it the most expensive part of drug development.
4
 It is evident that the shift of clinical 
testing to developing countries is largely driven by economics because poorer countries allow the 
drug to be approved faster and the trials are also cheaper.
5
 Secondly, citizens of developing 
countries are attractive targets for these clinical drug trials because they usually lack information 
about the reputations of the drug companies, and don’t have the same degree of access to their 
countries’ courts.6 In addition, clinical testing on human subjects in foreign countries makes it 
easier for the drug manufacturers to satisfy the FDA’s New Drug Application.7 Furthermore, 
because the pharmaceutical companies test their new investigational drugs on native populations 
of foreign countries, they are far from the regulations and reaches of the FDA, because the 
FDA’s limited financial capacity does not allow on site inspection of clinical testing centers, 
especially those that are located in foreign countries. While FDA rules must be satisfied for any 
drug approval in the U.S., the agency's oversight of distant trials is tenuous at best.
8
 Because of 
this oversight in regulation, the American consumers are sold “blood drugs,” which are drugs 
that reach the American homes at the cost of human lives and liberties due to foreign clinical 
                                                        
3
Abraham Lustgarten, Drug Testing Goes Offshore, FORTUNE, Aug. 8.2005, at 67, 69-70 
4
 Id. 
5
 Id. 
6
Shtilman, Supra note 1, at 427. 
7
 FDA is committed to protecting the participants of clinical trials, as well as helping to ensure that 
reliable information is provided to those interested in participating. FDA requires that potential 
participants give their informed consent before testing begins. Informed consent requires that the 
participants be given appropriate information about the study to enable them to decide whether to enroll 
in the clinical trial. FDA often provides extensive technical input to researchers conducting clinical trials, 
which may help them design better trials that can characterize effects of a new product more efficiently, 
while reducing risks to those participating in the trials. In addition, the clinical trial team includes doctors 
and nurses, as well as other health care professionals. In contrast, many developing nations do not have an 
effective regulatory or effective infrastructure and trial subjects are at risk of severe exploitation and harm 
with little chance of compensation. 
 http://www.fda.gov/forconsumers/consumerupdates/ucm134723.htm;  
8
 Samantha Evans, The Globalization of Drug Testing: Enforcing Informed Consent Through the Alien 
Tort Claims Act, 19 Temp. Int’l & Comp. L.J. 477, 479 (2005). 
 4 
participants being deprived of informed consent. This lack of informed consent proves to be 
disabling and deadly for the human test subjects who are unaware of the adverse effects of a 
potentially new and dangerous drug that is tested on infants, children and adults.  
  Other scholars have suggested allowing the victims of unethical drug testing a cause of 
action by demonstrating the violation of one or more principals of the Nuremberg Code
9
, and 
requiring Congress to enact a mechanism of criminal sanctions to deter human subject abusers. 
Unfortunately, both suggestions present solutions that will almost be unavailable to the mostly 
poor and illiterate human test subjects of developing counties who will neither have the resources 
nor the money to file an action against the wealthy pharmaceutical companies that are equipped 
with some of the best defense attorneys in the U.S. Therefore, in order to protect research test 
subjects from unethical treatment at these research test centers around the world, the FDA should 
require drug manufacturers to install video cameras at all of their clinical testing centers, whether 
it be domestic or international. This solution is better than the other solutions that have been 
presented because this requires the pharmaceutical giants, not the poor and abused trial subjects, 
to take action to protect the test subjects.  In order to explain this solution more in depth, this 
paper will discuss: (I) the Legislative history of drug regulation; (II) How the FDA Approves 
New Drugs; (III) Ethical Concerns About Treatment of Test Subjects (IV) International 
Regulations Regarding Treatment of Test Subjects; (V) The Solution; and (VI) Conclusion.  
 
 
 
                                                        
9
 Shtilman, Supra note 1, at 452.  
 5 
I. LEGISLATIVE HISTORY OF DRUG REGULATION 
 
Congress passed the Food and Drug Act in 1906.
10
 In 1938 Congress passed the Federal 
Food, Drug and Cosmetic Act (FFDCA), which required that drugs be proven safe before they 
could be sold in interstate commerce.
11
 Later, in 1962, Congress passed the Kefauver-Harris 
Drug Amendments to the FFDCA.
12
 The Kefauver Harris Drug Amendments required that drugs 
be proven effective as well.
13
 Today, for a drug to be approved under the FFDCA, the FDA has 
the responsibility of finding “substantial evidence of effectiveness.14 The statute states that 
substantial evidence consists of adequate and well-controlled investigations, including clinical 
investigations by experts who are qualified by scientific training and experience to evaluate the 
effectiveness of a new investigational drug.
15
 Therefore, in order to protect the safety of 
consumers, the legislature has amended the FFDCA and given authority to the FDA to find that a 
drug is safe and effective through thorough investigations and evaluations by experts.
16
 The 
                                                        
10
 Federal Food and Drug Act of 1906 (F&DA), P.L. 59-384, 1906 
11
 Federal Food, Drug and Cosmetic Act (FFDCA), P.L. 75-717, 1938.  
12
 Kefauver-Harris Drug Amendments to the FFDCA, P.L. 87-781, 1962. (50 Years: The Kefauver-Harris 
Amendments. www.fda.gov/Drugs/NewsEvents/ucm320924.htm. The Kefauver-Harris drug 
amendments, which have ensured prescription drug effectiveness and safety for 50 years. Id. But the 
legislation may not have been proposed if it had not been for the persistence of an FDA medical officer, 
and two U.S. congressmen. Id. The FDA medical officer reviewed an application for thalidomide, a 
widely prescribed drug for morning sickness during pregnancy in Canadian, African, and European 
countries. Id. Upon persistent inquiry and review, it was revealed that thalidomide was connected to 
severe birth defects and thousands of children in Europe were born with missing, shortened, or flipper-
like arms and legs. Id. When the Washington Post reported about FDA’s role in averting the thalidomide 
tragedy in the United States, and the Kefauver-Harris Amendments to FDCA gave FDA weight to 
demand that drug makers prove their products were safe and effective before receiving approval to market 
them in the United States. Id. 
13
 Id. 
14
 21 U.S.C. § 355(d). 
15
 Id. 
16
 Id. 
 6 
legislature also requires manufactures to obtain FDA approval prior to marketing a prescription 
drug in the United States.
17
 
 
II. HOW THE FDA APPROVES NEW DRUGS 
 
  The drug approval process begins before the FDA gets involved. During a new drug's 
early preclinical development, the sponsor (usually the manufacturer or potential marketer) has 
the responsibility of determining whether the product they are seeking to manufacture and 
market is reasonably safe for initial testing in humans.
18
 When a product is identified as 
reasonably safe for further testing, the sponsor then focuses on collecting the data and 
information necessary to establish that the product will not expose humans to unreasonable risks 
when used in limited, early-stage clinical studies.
19
 This is usually established through testing on 
animals.
20
 FDA's role in the development of a new drug begins after the drug's sponsor has 
screened the new molecule for pharmacological activity and acute toxicity potential in animals 
and wants to test its diagnostic or therapeutic potential in humans.
21
  At that point, the molecule 
changes in legal status under the Federal Food, Drug, and Cosmetic Act and becomes a new drug 
subject to specific requirements of the drug regulatory system.
22
 There are four steps in the 
approval of new drugs for marketing in the United States.  
                                                        
17
 FFDCA, § 503(b)(1) 
18
  FDA, “Approval and Development Process (Drugs)”: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approva
lApplications/InvestigationalNewDrugINDApplication/default.htm; CRS Report R41705, The National 
Institutes of Health (NIH): Organization, Funding, and Congressional Issues, by Judith A. Johnson and 
Pamela W. Smith, provides that basic research is done in labs while clinical research involves a large 
amount of volunteers to test the new drug. 
19
 Id. 
20
 Id. 
21
 Id. 
22
 Id. 
 7 
A. Investigational New Drug (IND) Application 
A manufacture seeking to market a new drug must file an IND application with the FDA 
before clinical testing.
23
 The IND must include information about preclinical data to access 
whether the product is reasonably safe for clinical testing, which usually includes animal and 
pharmacology studies.
24
 The IND must also include information about the composition and 
manufacturer of a drug in order for the FDA to determine whether the company can adequately 
produce and supply the drug consistently.
25
 Lastly, the IND application must also contain 
detailed protocols for proposed clinical studies to assess whether the clinical trials could be 
subject to harm and that risk of harm will be explained to the clinical trial participants.
26
 Once 
the IND is submitted, the sponsor must wait 30 calendar days before initiating any clinical 
trials.
27
  During this time, FDA has an opportunity to review the IND for safety to assure that 
research subjects will not be subjected to unreasonable risk.
28
  
B. Clinical Trials 
Clinical trials, also known as clinical studies, test potential new drugs in human volunteers 
to see whether they should be approved for wider use in the general population.
29
 Clinical trials 
are done at hospitals and research centers around the country, and they are divided into three 
phases: Phase 1, phase 2, and phase 3.
30
 Phase 1 trials usually involve a small number of healthy 
volunteers to try to determine dosing, how a drug is metabolized and excreted, and identify 
                                                        
23
 FDA, “Investigational New Drug Application” (IND):  
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approva
lApplications.htm 
24
 Id. 
25
 Id. 
26
 Id. 
27
 Id. 
28
 Id. 
29
 FDA, “Inside Clinical Trials: Testing Medical Products in People; What Is a Clinical Trial?” 
Information for Consumers, http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htm. 
30
 Id. 
 8 
acute side effects.
31
 Phase 2 trials include more participants (about 100-300) who have the 
condition that the investigational new drug potentially could treat and researchers gather safety 
data and preliminary evidence of the drug's efficacy and develop research methods for future 
trials involving this new drug.
32
 The investigational new drug only moves on to phase 3 if the 
phase 2 trials are indicative of the drug being effective and the risks are considered acceptable.
33
 
In phase 3 trials, the drug is studied in a larger number of people (approximately 1,000-3,000) 
infected with the disease that the drug seeks to cure.
34
 This phase continues to test the product's 
effectiveness and monitors side effects.
35
 The rationale behind this further testing is that as an 
increasing number of participants are tested over increased spans of time, the less common side 
effects are more likely to be revealed.
36
 
C. New Drug Application 
   After the clinical trials are completed, the manufacturer must then submit a New Drug 
Application (NDA) to FDA’s Center for Drug Evaluation and Research (CDER).37 The NDA 
contains clinical trial results, information about the manufacturing process and facilities, and a 
                                                        
31
 Phase 2 and Phase 3 clinical trials generally have a control standard. What that means is that one group 
of volunteers are given the experimental new drug or treatment, while the control group is given either a 
standard treatment for the illness or an inactive pill has no treatment value (placebo). This control group 
provides a basis for comparing the effects of the investigation drugs as compared to the placebo or 
standard drug. Id. 
32
 Id. 
33
 Id. 
34
 Id. 
35
 Some treatments being studied can have unpleasant, or even serious, side effects. Often these are 
temporary and end when the treatment is stopped. Others, however, can be permanent. Some side effects 
appear during treatment, and others may not show up until after the study is over. The risks depend on the 
treatment being studied and the health of the people participating in the trial. Id. 
36
 Id. Note: Sometimes, Phase 4 trials are conducted after a product is already approved and on the market 
to find out more about the treatment's long-term risks, benefits, and optimal use, or to test the product in 
different populations of people, such as children. Id. 
37
 New Drug Application (NDA) 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/Approva
lApplications/NewDrugApplicationNDA/default.htm  
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description of the potential new product.
38
 Since 1938, the FDA has required that each drug have 
an approved NDA before it can be marketed in the United States.
39
 As the NDA is the medium 
through which drug sponsors petition the FDA to approve a new drug, the informational data 
gathered through the animal studies and human clinical trials become part of the NDA.
40
 The 
goals of the NDA are to provide enough information to permit FDA reviewer to decide whether 
the drug is safe and effective for it’s proposed use and the benefits of the new drug outweighs the 
risks.
41
 In addition, the reviewer also determines whether the labeling and packaging methods are 
appropriate and whether the methods used to manufacture the drugs are adequate to preserve the 
drug’s quality, purity, and identity.42  
 In sum, for a new drug to be approved, the FDA must find “substantial evidence” of 
effectiveness from the data of adequate and well-controlled clinical trials.
43
 Because the approval 
process requires the data from clinical studies, the potential new drugs have to be tested on 
humans in clinics before they are marketed in the United States.
44
  
 
III. ETHICAL CONCERNS ABOUT TREATMENT OF TEST SUBJECTS 
 
Due to the large number of participants required for testing investigational new drugs, 
there is an obvious need for a large number of volunteers who will participate in the clinical 
testing of the investigational new drug. Western medicine has relied on human and animal 
experimentation since ancient times. It was by dissecting the bodies of criminals and the poor, 
                                                        
38
 Id. 
39
 Id. 
40
 Id. 
41
 Id. 
42
 Id. 
43
 21 U.S.C. § 355(d) 
44
 Id. 
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for example, that Greek physicians discovered the nervous system in 300 B.C.
45
 But it was only 
after the rigorous experimental design called the controlled clinical trial emerged in the 1940s 
and was codified into U.S. law in 1962, that the global hunt for experimental bodies began in 
earnest.
46
 To their chagrin, pharmaceutical manufacturers have found Americans increasingly 
hesitant to participate in drug experiments because of skepticism about their safety.
47
 This 
reluctant attitude of Americans is due to the ill reputation of pharmaceutical companies who are 
often maligned for putting profits before patients.
48
 The well-publicized allegations of failures to 
warn of an investigational drug’s harmful side effects is one of the many reasons that can be 
attributed to the negative image of the pharmaceutical companies.
49
 Today, industry investigators 
can count on failing to find sufficient numbers of willing test subjects on time in four out five of 
their clinical trials.
50
 Along with shortage of test subjects in America, pharmaceutical companies 
have another reason to be worried. Everyday a new drug remains locked in development, it 
bleeds companies of up to 1 million dollars in potential sales income.
51
 This loss of money puts 
pressure on the pharmaceutical companies to put new drugs to the market at the earliest. Because 
of these concerns, pharmaceutical companies are reaching out to Contract Research 
Organizations (CROs).
52
 CROs are independent contractors who perform clinical trials more 
                                                        
45
 ROY PORTER, THE GREATEST BENEFIT TO MANKIND: A MEDICAL HISTORY OF 
HUMANITY 67 (1997). 
46
 SONIA SHAH, THE BODY HUNTERS: TESTING NEW DRUGS ON THE WORLD’S POOREST 
PATIENTS 6, (2006). 
47
Shtilman, Supra note 1, at 432 
48
 Id. 
49
 Id. citing, Joel Slawotski, International Product Liability Claims Under the Alien Tort Claims Act 16 
Tul. J. Int’l & Comp. L. 157, 168 (2007). 
50
 SHAH, Supra note 46, at 5 
51
 Id. citing Stan Barnard, “The Drug Drought: Primary Causes, Promising Solutions,” Pharmaceutical 
Executive, November 2002, 7. 
52
  Mary Pat Flaherty et al., The Body Hunters: Testing Tidal Wave Hits Overseas, Wash. Post, Dec. 18, 
2000, at A1 
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quickly and are more aggressive in finding patients for the clinical trials.
53
 CROs provide local 
expertise and recruit doctors who perform the clinical trials.
54
 Many of these trials are being 
conducted in developing countries, including the rapidly evolving countries of Eastern Europe 
and the Russian Federation.
55
 This swift move to foreign countries motivated by the 
pharmaceutical companies’ desire to save money and find recruits more easily.56 A 
pharmaceutical executive reported that a medical center in India charges approximately $1500 to 
$ 2000 per case report, which is less than one tenth the cost of second-tier center in the United 
States.
57
Also, there is a large pool of research participants in countries such and India and China, 
which helps accelerate recruitment.
58
 In addition, foreign clinical trials are more attractive to the 
pharmaceutical companies because the regulatory barriers in those countries are less strict.
59
      
There are also benefits of conducting trials in developing countries that include fostering 
positive relationships around clinical investigators globally and answering questions about the 
safety and efficacy of drugs that are of interest throughout the world.
60
 Although there are a few 
benefits, the major concern of testing drugs overseas is the unethical treatment of human test 
subjects across the globe. Dr. Arthur Caplan, director of the Center for Bioethics at University of 
Pennsylvania’s Perelman School of Medicine voiced some of these ethical concerns in his 
interview with PBS’s News Hour. Dr. Caplan explained that along with it being cheaper to 
recruit participants for clinical research in developing countries, the citizens of these target poor 
                                                        
53
 Emilie Reymond, CRO Supremacy in Clinical Research Raises Concerns: http://www.outsourcing-
pharma.com/Clinical- Development/CRO-supremacy-in-clinical-research-raises-concerns. 
54
 SHAH, Supra note 3, at 437. 
55
 Ethical and Scientific Implications of Globalization of Clinical Research: 
www.nejm.org/doi/full/10.1056/NEWJMsb0803929 
56
 Id. 
57
 Id. 
58
 Id. 
59
 Id. 
60
 Id. 
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countries are not taking other medications that could interfere with the data in the new drug.
61
 
This is due to the population in these target countries being poor and generally not being able to 
afford medication for any ailments they might suffer.
62
 Furthermore, there are ethical concerns 
about informed consent.  Dr. Caplan expressed concern over whether the participants in these 
poor countries actually give informed consent or do they just sign up for anything because they 
trust doctors or they are in desperate need of money or medicine? 
63
 Another concern is the 
reliability of data from these poor nations. Data might not be reliable because the people might 
not take the pills as prescribed or they might be getting other side effects they might not report.
64
  
These concerns come to life in foreign clinical centers in poor countries with large 
populations who cannot afford to go to a doctor or get proper medication. For instance, India, the 
most populous country in the world, has a large and diverse population.
65
 India is a hotspot for 
clinical testing because it has an underprivileged and drug-naïve patient population who embrace 
the chance to participate in a clinical trial as a healthcare-windfall.
66
 India’s inadequate 
healthcare system, low costs for clinical trials, and corruption make India an attractive 
destination for clinical trials where pharmaceutical companies exploit the weaknesses of the poor 
citizen of these countries.
67
 In addition, proper trial procedures may not be followed at these 
clinical testing centers. An example of such concerns came to life in the poor state of Madhya 
Pradesh in India. There, to put an end to the unethical treatment of the test subjects, local health 
                                                        
61
 Miller, Talea. ‘Explosive’ Growth in Foreign Drug Testing Raises Ethical Questions.’ 
www.pbs.org/newshour/rundown/2011/08/sending-us-drug-research.htm 
62
 Id. 
63
 Id. 
64
 Id. 
65
 Samiran Nundy & Chandra m. Gulhati, A New Colonialism Conducting Clinical Trials in India, 325. 
Eng. J. Med. 1633, 1634 (2005). 
66
 Shtilman, Supra note 1, at 440, citing, James Cekola, Outsourcing Drug Investigations to India: A 
Comment on U.S., Indian and International Regulation of Clinical Trials in Cross-Border 
Pharmaceutical Research, 28 NW. J. INT'L L. & BUS. 125, 126 (2007). 
67
 Id. 
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activists filed formal complaints with the state and national human rights commissions, and the 
government controller.
68
 As a result, the Indian government investigated practices at a certain 
public hospital where 73 clinical trials were performed on 3300 patients, including 1833 
children, some of whom reported adverse affects and even died.
69
 The investigation revealed that 
volunteers at that hospital did not give informed consent because the details were in English, 
among other shortcomings.
70
 A World Health Organization representative to India acknowledged 
that there were concerns that vulnerable populations were exploited and informed consent 
processes were not followed in Madhya Pradesh.
71
 Such exploitations occurred because doctors 
were paid heavily and given other benefits such as paid trips abroad to attend conferences.
72
 
These financial incentives motivated the doctors to cut corners and not follow the rules.
73
 
Another example of vulnerable populations being exploited at the hands of giant pharmaceutical 
companies is demonstrated in the case of Abdullahi v. Pfizer, Inc.
74
 In that case, Pfizer, the 
world’s largest pharmaceutical company conducted clinical trials in Nigeria to test its new 
antibiotic Trovan.
75
 In the process of developing this new antibiotic, Pfizer seized the 
opportunity to perform clinical testing of this investigation new drug on a Nigerian population 
that had just suffered epidemics of meningitis, measles, and cholera.
76
 Pfizer set up a medical 
treatment center in Nigeria.
77
 Pfizer’s new drug had only been tested on one child before the 
                                                        
68
 World Report. Regulation Failing To Keep Up With India’s Trials Boom. www.thelancet.com  
69
 Id. 
70
 Id. 
71
 Id. 
72
 Id. 
73
 Id. 
74
 Abdullahi v. Pfizer, Inc., No. 01 Civ. 8118, 2002 U.S. Dist. LEXIS 17436, at *2-3 (S.D.N.Y. Sept. 16, 
2002) 
75
 Id. at 2 
76
 Id. 
77
 Id. 
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clinical trial in Nigeria.
78
 Animal testing of Trovan had demonstrated that it might lead to side 
effects in children such as joint disease, abnormal cartilage growth and liver damage.
79
 Although 
Pfizer sought permission from the parents of the children on whom the research would be done, 
few parents read or spoke English.
80
 In addition, it was also alleged that Pfizer did not explain 
that the proposed treatment was only experimental and the subjects were allowed to refuse it.
81
 
Pfizer’s medical team left Nigeria after the clinical trials and never followed up with the subjects 
about the complications they might have suffered.
82
 As a result of the clinical trials, several 
Nigerian minor children died and many others suffered paralysis, deafness, and blindness as side 
effects of Trovan.
83
 This case demonstrates that citizens in poor countries, especially those with 
no medical facilities fall prey to the pharmaceutical companies’ clinical trials, mainly because 
informed consent procedures are not followed.  
In contrast, if the clinical trials were conducted in the United States, the subjects would at 
least have a legal cause of action and standing to file a suit against the pharmaceutical companies 
for failing to give informed consent or any other wrongs. Most clinical trials are federally 
regulated with built-in safeguards to protect participants and the Office for Human Research 
Protections (OHRP) in the Department of Health and Human Services (HHS) leads the 
department's programs for the protection of human research participants and oversees human 
protection in HHS-funded research.
84
 The FDA has authority over clinical trials for drugs and 
regulates studies that are HHS-funded (with joint oversight by the FDA and the OHRP), as well 
                                                        
78
 Id. 
79
 Id. 
80
 Id. 
81
 Id. 
82
 Id. 
83
 Id. 
84
 FDA:  http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143531.htM 
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as studies that are solely funded by industry or by private parties.
85
 Clinical trial procedures are 
reviewed by institutional review boards (IRBs) and they ensure that appropriate steps are taken 
to protect the rights and welfare of participants as subjects of research.
86
 IRBs also review 
participant inclusion and exclusion requirements to be sure that appropriate people have been 
identified as eligible for the trial. Most importantly, the IRBs review the adequacy of the 
informed consent document to make sure that it includes all the elements required by law, and 
that it is at an appropriate reading level and understandable to study participants.
87
 The informed 
consent is the most cogent of human subject protection and 21 C.F.R. § 50.25 requires 
researchers to explain eight factors to volunteers:  
(1) The purpose, extent and procedures of the trial;  
(2) Reasonably foreseeable risks;  
(3) Expected benefits;  
(4) Alternative procedures that may be advantageous to the patient;  
(5) Confidentiality of the trial's records;  
(6) Compensation for injuries;  
(7) A contact point for questions about the research; and  
(8) The voluntary character of participation.
88
 
The federal law affords children even greater protections in research.
89
 Generally, researchers 
must obtain parents’ consent as well as the child’s assent, and any research posing more than a 
                                                        
85
 Id. 
86
 Id. 
87
 Id. 
88
 21 C.F.R. § 50.25 
89
 45 C.F.R. § 46.401. See generally Committee on Clinical Res. Involving Child., Inst. of Med. of the 
Nat'l Acad., Ethical Conduct of Clinical Research Involving Children (Marilyn J. Field & Richard E. 
Behrman eds., 2004) 
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minimal risk to the child subject must also directly benefit the child.
90
 Hence, if Pfizer had 
conducted the clinical trials of Trovan in America, they would have to follow strict informed 
consent procedures. In addition, the plaintiffs would be very strongly protected by the federal 
law, especially the children, and would have a solid cause of action against Pfizer for any 
misdoings and disabling and life-threatening adverse effects of Trovan.  
In addition to providing protection for clinical trial subjects in the United States, the FDA 
also conducts inspections of clinical trial sites to determine if the clinical investigators are 
conducting clinical studies in compliance with applicable statutory and regulatory 
requirements.
91
 Clinical investigators who conduct FDA-regulated clinical investigations are 
required to permit FDA investigators to access, copy, and verify any records or reports made by 
the clinical investigator with regard to, among other records, the disposition of the 
investigational product and subjects’ case histories.92 The FDA investigator typically performs 
this oversight function through on-site inspections designed to document how the study was 
actually conducted at the clinical investigator’s site. 93 The FDA conducts both announced and 
unannounced inspections of clinical investigator sites, typically under the following 
circumstances:   
1. To verify the accuracy and reliability of data that has been submitted to the agency;   
2. As a result of a complaint to the agency about the conduct of the study at a particular 
investigational site;   
3.  In response to sponsor concerns;  
4.  Upon termination of the clinical site;   
                                                        
90
 Id. 
91
 FDA: Regulatory Information: 
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126553.pdf 
92
 See 21 CFR 312.62(c) 
93
 Id. 
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5. During ongoing clinical trials to provide real-time assessment of the investigator’s 
conduct of the trial and protection of human subjects;   
6.  At the request of an FDA review division; and   
7.  Related to certain classes of investigational products that FDA has identified as products  
of special interest in its current work plan.
94
 FDA’s authority to inspect clinical testing centers in 
America also extends to clinical trials abroad.
95
 Even if sponsors of clinical trials conducted 
outside the U.S. are not required to file an IND, sponsors submitting foreign clinical studies not 
conducted under an IND to FDA must comply with requirements in 21 CFR 312.120.
96
  If a 
clinical investigator conducts a study under an IND outside of the U.S., the clinical investigator 
is subject to FDA regulations, including applicable provisions in 21 CFR parts 50, 56, and 312.
97
      
Although the FDA has guidelines for inspections at foreign clinical trials, the Department of 
Health and Human Services Office of Inspector General (OIG) released a report raising 
questions about the FDA’s capacity to monitor the safety of clinical trials conducted in foreign 
countries.
98
 The report found that eighty percent of approved marketing applications for drugs 
contained data from foreign clinical trials and over half of the clinical trial subjects were located 
outside the United States.
99
 In addition, the report showed that FDA inspected clinical 
investigations at 1.2 percent of clinical trial sites for applications approved in the year 2008.
100
 
Furthermore, the FDA inspected clinical investigators at only 0.7 percent of foreign clinical 
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sites.
101
 Also, the report raised concerns that FDA could have been unaware of some ongoing 
early-phase clinical trials because sponsors conduct early-phase clinical trials outside the United 
State without obtaining INDs.
102
 One of the reasons that the FDA rarely conducts inspections of 
foreign clinical sites is time.
103
 According to the report, inspectors are generally allowed only 1 
week, including travel time to conduct the inspections. Obtaining work visas and translators are 
also among the challenges faced by the FDA inspectors. Lastly, and most importantly, the FDA 
does not have sufficient funds to conduct the inspections overseas because inspections are 
expensive and may not always be cost effective. 
104
 With inspections costing about $ 40,000 each 
and the additional challenges faced above, it really is difficult to physically perform 
investigations at foreign clinical sites.
105
 
  The report “highlights a very frightening and appalling situation,” said Representative 
Rosa DeLauro, Democrat from Connecticut. “By pursuing clinical trials in foreign countries with 
lower standards and where F.D.A. lacks oversight, the industry is seeking the path of least 
resistance toward lower costs and higher profits to the detriment of public health.” In addition to 
the monetary challenges, the agency has also had a very poor record-keeping system that 
recorded data submissions from drug makers that do not adhere to standardized formats.
106
 From 
example, the F.D.A. was unable to provide Mr. Levinson’s investigators with detailed clinical 
trial data for 29 out of 129 of the approved applications in 2008.
107
 For eight of the applications, 
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the agency could not locate any part of the application.
108
 Daniel R. Levinson, the inspector 
general the Department of Health and Human Services who composed the report suggested that 
the agency should switch to an electronic database and demand that drug companies submit their 
data in an electronic format.
109
 He wrote that, “As sponsors increase the number of foreign 
clinical trials in support of F.D.A. marketing applications, the agency’s current method of using 
inspections to ensure human subject protections and data validity is becoming increasingly 
strained.”110 He also encouraged the FDA to develop more cooperative inspection agreements 
with foreign governments, inspect more clinical trials in more countries and tell companies to 
register their clinical trials before administering them.
111
  
 From a regulatory and an ethical standpoint, the risks associated with outsourcing clinical 
trials overseas that lack FDA oversight, pose threat to the safety and health of human test 
subjects.
112
 Even though the clinical trials that are managed by the CROs for American 
pharmaceutical companies are subject to FDA regulations and inspections, these regulations can 
be circumvented more easily when trials are conducted overseas, exposing participants to health 
risks as new drugs are “speeded” to the market.113 To add to the risk factors, governments who 
wish to attract drug companies to conduct drug trials within their borders have strong incentives 
to encourage lax national and local oversight of the research.
114
 Furthermore, the FDA, pursuant 
to FFDCA, allows companies to submit drugs for FDA approval even if the pharmaceutical 
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company’s trial data is based exclusively on the results of clinical trials that were conducted 
overseas as long as the foreign data is applicable to the U.S.’s medical practice and population, 
and the studies have been performed by recognizably competent clinical investigators.
115
 
Therefore, because the regulatory bodies are often structured to monitor the quality of clinical 
trial data and the safety of drugs in their domestic markets,
116
 the clinical trials abroad are bound 
by a very lenient FDA regulation. Moreover, other international regulations do not prove to be 
more help the injured plaintiffs either. 
 
IV. INTERNATIONAL REGULATIONS REGARDING RESEARCH ON HUMAN 
SUBJECTS 
 
 
As mentioned earlier, in Abdullahi v. Pfizer, several Nigerian minors died and a number 
of them suffered from paralysis, deafness, and blindness because of their treatment with 
Trovan.
117
 In that case, many of the effected Nigerian minors and their guardians brought a class 
action suit against Pfizer.
118
 They filed a claim for a violation of the law of nations under the 
Nuremberg Code (Code), the Declaration of Helsinki (Declaration), and the International 
Covenant on Civil and Political Rights (ICCPR), but did not win on the basis of either of 
them.
119
 This part of the paper will examine the standards that the plaintiffs in Abdullahi v. Pfizer 
sued under, as well as the guidelines by the World Health Organization (WHO). 
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A. The Nuremberg Code 
The Code presents ten principles to determine the boundaries of permissible medical 
experimentation on human subjects.
120
 The Code says that informed consent is absolutely 
essential and goes on to list other principles that protect the welfare of the research subjects. 
However, the Code does not contain any language that would require the researchers to abide by 
it. The Code is a suggestion that can be adopted by countries and made into a mandatory law.  
 
B. The Declaration of Helsinki 
 The Declaration of Helsinki was issued in 1964 and provides guidance to physicians 
involved in medical research involving human test subjects.
121
 In its principles, the Declaration 
advises physicians to protect the life, health, privacy and dignity of the human test subjects and 
use caution when conducting research.
122
 In addition, the Declaration requires that informed 
consent should be documented and witnessed.
123
 Furthermore, it also requires a balancing of 
interests and advises that research should only be conducted if the benefits outweigh the risks.
124
 
However, like the Nuremberg Code, the Declaration of Helsinki provides guidelines, but not 
specific rules. 
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   C. International Covenant on Civil and Political Rights 
  The ICCPR is the only legally binding international treaty concerning human 
experimentation.
125
 The ICCPR comprises all of the traditional human rights as they are known 
from historic documents such as the First Ten Amendments to the Constitution of the United 
States (1789/1791) and the French Déclaration des droits de l’homme et du citoyen (1789).126 
Specifically, Article 7 requires informed consent, and prohibits torture and cruel or inhuman 
treatment or punishment.
127
  
D. WHO-CIOMS Guidelines 
 
  In 1982, the World Health Organization and Council for International Organization of 
Medical Sciences published the Proposed International Ethical Guidelines for Biomedical 
Research involving Human Subjects (“Guidelines”).128 The Guidelines were intended to serve as 
an example to nations who wanted to draft legislation on human research.
129
 Specifically, 
guideline 4 requires individual informed consent for all biomedical research involving humans 
and the commentary to this guideline further explains what should be done with respect to the 
process, language, comprehension, documentation, and cultural considerations involved with 
informed consent.
130
 Guidelines 5, 6, and 7 also relate to informed consent and discuss essential 
information for prospective research subjects, obligations of sponsors and investigators, and 
inducement to participate and propose a balancing of interests, favoring benefits over risks.
131
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Although WHO advocates that the nations adopt its guidelines regarding research on human test 
subjects, the advisory guidelines have not proven sufficient to prevent violations and abuses in 
clinical research taking place in developing countries.
132
 
 
IV. THE SOLUTION 
 
 As an increasing number of test subjects are enrolled in clinical drug trials all over the 
globe, researchers and doctors, many of whom are corrupt, are reporting failures in compliance 
with ethical standards because there is no positive law that governs ethical standards abroad.
133
 
Today, the greatest obstacle to ensuring health and safety of participants in overseas trials is 
largely due to the lack of regulation over the independent contractors that work for Western 
pharmaceutical manufacturers.
134
 In addition, the FDA does not demand compliance with the 
U.S law where international test subjects are concerned.
135
 The FDA advises applicants that “if 
the drug is manufactured outside of the U.S. or its territories, the trials sites are all outside the 
U.S., and the trial is not being conducted under an [investigational new drug application], then it 
would not be considered to be subject to section 505 of the [Food, Drug, and Cosmetic] Act or 
section 351 of the [Public Health Service] Act, and the clinical investigation would not be an 
“applicable drug clinical trials.””136 In order to protect the human test subjects who are located 
outside the U.S. (who are not protected by the FDA), there have been proposals to stop the 
unethical treatment of human test subjects in international clinical trial investigations. One 
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proposal seeks to allow the victims a cause of action by demonstrating the violation of one or 
more principles of the Nuremberg Code, a cause of action that would allow the victim to hold 
accountable the researcher conducting the drug trial as well as the pharmaceutical company 
sponsoring the trial and the CRO overseeing the researcher’s activities.137 However, this solution 
seems unviable because, although allowing a cause of action under the Nuremberg Code might 
give the injured plaintiffs some relief, this proposal is unlikely to stop the testing centers from 
continuing with their unethical practice of exploiting human subjects for several reasons. Firstly, 
the test subjects may not have enough knowledge about the laws and may never find out that 
there is any such cause of action that can grant them relief. Secondly, many of the test subjects in 
poor and populous countries such as India volunteer themselves at these research centers because 
of the need for money and medicine.
138
 It is highly unlikely that such poor individuals will have 
the money or the resources to sue the big pharmaceutical companies. Thirdly, the corruption and 
the greed of local doctors will trump ethical treatment of human test subjects as many of the 
physicians conducting research for the pharmaceutical companies as well as the research 
institutions where the research takes place, have a financial interest in the studies because they 
are paid heavy sums for conducting and approving the trials.
139
 Lastly, the cost developing new 
drugs in the United States has grown to near one billion dollars that include conducting 
preliminary research, clinical research on human test subjects, and fulfilling FDA 
requirements.
140
  By transferring costly trials to countries with fewer regulatory hurdles
141
, a 
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pharmaceutical company can gain significant profits, which, when compared with the monetary 
damages they would have to pay for a claims by a few injured plaintiffs, might be significantly 
higher. Therefore, it might just be easier and less costly for the pharmaceutical companies to pay 
the plaintiffs their damages instead of delaying the testing of their investigational new drug, and 
thereby losing profits.  
  Rather than requiring the poor and injured plaintiffs in corrupt countries to take action to 
get any sort of monetary relief, a better solution would be to require the rich pharmaceutical 
companies to take action to ensure ethical treatment of human test subjects. Daniel R. Levinson, 
the inspector general the DHHS suggested that the FDA agency should switch to an electronic 
database and demand that drug companies submit their data in an electronic format.
142
 Although 
his suggestion would not solve the problem of unethical treatment of human test subjects, it does 
suggest that the FDA switch to modern methods of data keeping and inspecting testing centers. 
Therefore, in order to solve the problem of unethical testing of human test subjects, my solution 
is that the FDA should be given authority to require video cameras at all domestic and foreign 
clinical research and testing centers. These cameras should be streaming live surveillance videos 
over the internet, so that testing can be recorded and monitored in real-time. One benefit of this 
would be that all activities of the clinical center would be recorded, if not constantly monitored 
by someone. This constant video monitoring would produce many beneficial outcomes. Perhaps 
these benefits can best be explained by comparing them to the benefits of video surveillance used 
in other highly reputed institutions. One example where video surveillance is used to ensure that 
ethical guidelines are being followed can be found at Seton Hall Law School, located in Newark, 
New Jersey. A recent mass email sent out to the law students during final exams period said that 
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there would be no exam proctors in some rooms where the exams would be administered.
143
 
Instead, the school would use a virtual proctoring system that allows video and audio 
transmission and live communication between the students and the Registrar’s office.144 The 
emails further explained that the school opted to use the virtual proctoring system to ensure the 
academic integrity and allow students to alert the Registrar’s Office in case of a problem during 
the exam without leaving the exam room.
145
 In addition, the staff at the law school would also be 
able to remotely notify students when their exam time had ended.
146
 Similarly, mandatory video 
surveillance at research testing centers will ensure the ethical treatment of research test subjects 
around the globe. Accordingly, the FDA should also be given authority to require that informed 
consent be given in front of the video cameras. This will make certain that informed consent is 
actually given, and it is given in the native language of the test subjects, and the test subjects 
only give consent after they are informed that the drug is not a cure but only an experimental 
drug that can possibly have adverse effects, sometimes even fatal. In a step ahead of the FDA,  
hospitals have begun their move towards remote video surveillance in the hospitals.  
  Many medical facilities and hospitals have already seen the benefits of video cameras in 
the workplace. A hospital in Alaska has implemented an upgrade to its CCU (Critical Care Unit), 
calling it an eICU (electronic Intensive Care Unit), and installed super high tech cameras on one 
side of seven rooms in the CCU.
147
 Below the camera, there is a monitor and a big red alert push 
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button that a nurse can push at any time.
148
 Once the button is pushed, either a certified critical 
care nurse or physician from Providence Alaska Medical Center appears on the monitor.
149
 The 
physician is available from 9 p.m. to 7 a.m., while other health care providers trained in intensive 
care are available 24 hours a day, seven days a week.
150
 In a demonstration of how this high tech 
system works, the CCU director pushed the red button.
151
 Almost instantly, a person appeared on 
the video screen and rotated the angle of the camera to see the people in the room.
152
 Next, to 
show off of the superior features of the camera, a piece of paper was placed on the pillow of the 
bed across the room from the camera.
153
 The person on the screen was able to read the contents 
of the paper.
154
 The rooms at the hospital are also equipped with microphones so that any person 
from the hospital can communicate with anyone in the room.
155
 In another instance, at another 
hospital in Florida, a doctor monitored a heavily bleeding patient through the video camera while 
working from a command center in a nearby office building.
156
 The same doctor was remotely 
monitoring her and other patients in six intensive-care units in three different hospitals.
157
 The 
monitoring system uses two-way video cameras, through which, the doctors in the command 
center can identify warning signs that a patient is taking a turn for the worse, advise bedside staff 
on giving medications and treatments, and point out potential errors or oversights. 
158
  
  Accordingly, keeping the benefits of these hospitals receive from remote video 
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monitoring in mind, the FDA should be amended so that it becomes mandatory for 
manufacturers seeking approval of a new drug, to set up video cameras in the testing facility 
where they plan to test the drug. FDA inspectors who are qualified and authorized to conduct 
physical inspections of the testing centers can monitor that facility remotely. Some of the 
benefits that the FDA will obtain through this remote monitoring system can best explained by 
analyzing the list of benefits given by Safe-n-secure, a company that provides video surveillance 
in hospitals.
159
 On their website, that company explains that video surveillance would benefit 
hospitals because it would:  
1. Increase the overall security and safety of the hospital administration and the patients as the 
security cameras help in preventing crimes and breaks in and also allow operators to watch for 
troubled patients who may wander out of their rooms at night; 
2. Improve worker productivity because the presences of surveillance cameras on the premises 
can improve communication between hospital departments or buildings, allowing for heightened 
productivity; 
3. Prevent dishonest claims in instances where patients or visitors make false claims of injuring 
 
themselves on hospital property. Visual evidence from the facility's security cameras can 
 
prove that these claims are unwarranted and in turn, save the hospital from pricey lawsuits; 
 
5. Allow for continuous real-time monitoring so that authorized hospital employees can monitor 
critical areas continuously, in real time, from their personal computers. 
6. Allow for Digital store, which would enable the user to store recorded footage digitally on 
network servers where the surveillance video is easily accessible to authorized users, and offers 
improved searching capabilities; 
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7. Have visual evidence for investigations as video cameras can provide invaluable visual 
 
evidence for investigations of criminal activity and other specific events that have taken place 
 
at the healthcare facilities.
160
 
 
 Accordingly, the benefits of remote video monitoring will also be similar.  
Firstly, the video surveillance will most likely decrease the chances of unethical treatment as 
informed consent procedures will be recorded to see if they are performed correctly. Secondly, it 
will mostly likely increase the efficiency of the staff at the testing centers and serve as a crime-
prevention medium. The presence of video cameras as testing centers can deter some of the 
illegal activities happening at the testing centers and deter the staff at the testing centers from 
treating the test subjects unethically. Video surveillance is used in other industries for crime 
prevention purposes. The private sector began using Close Circuit Television (CCTV) 
surveillance in banks in the early 1960s, as mandated by federal law, and later in commercial 
buildings.
161
 By the 1970s, CCTV surveillance was also in use in hospitals, all-night convenience 
stores, art galleries, and in many other commercial locations.
162
 Borrowing from these industries, 
the regulations should be changed so that FDA is given the power to demand the pharmaceutical 
companies to install video cameras as research testing centers. Through this mechanism, the 
FDA will be equipped with the necessary resources to stop the inhumane treatment of human test 
subjects around the globe. Thirdly, video surveillance will also provide the FDA with the proof 
and ability to sanction drug companies that manufacture drugs in case of reports of adverse 
effects of the drug. One possible explanation for the FDA’s inability to change pharmaceutical 
companies’ conduct in developing overseas studies is a lack of severe sanctions when 
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researchers exploit foreign subjects.
163
 This problem would be easily resolved if the evidence 
needed to sanction is readily available through the recorded footage from the drug testing 
centers. Fourthly, to help protect the rights and welfare of volunteers and verify the quality and 
integrity of data submitted for review, the FDA performs inspections of clinical trial study sites 
and anyone involved in the research.
164
 However, because of the FDA’s limited funding, the 
inspections rarely take place in domestic clinical testing centers, and almost never in foreign 
clinical testing centers. To resolve this problem, the FDA should require the same inspectors who 
are responsible for physical inspections of clinical testing centers, to audit the videotapes to 
make sure that safety procedures are followed. Auditing a large quantity of video footage of the 
entirety of the trial at numerous locations around the world would be time consuming and not 
very productive. Hence, the pharmaceutical companies should be asked to perform the most 
important procedure informed consent procedures at the beginning of the trial, in front of the 
cameras. The nexus of informed consent is that it be done in the test subject’s native language if 
they do not understand English. The remote monitoring would encourage the researchers that the 
backbone of ethical guidelines, the informed consent procedure, is performed properly and 
efficiently. In addition, the video footage can also be consulted if there is an issue about the 
informed consent procedures not being followed properly. In the case of Abdullahi v. Pfizer, the 
plaintiffs claimed that they had suffered because the informed consent procedures were given in 
English, and not in then native language of the test subjects.
165
 The video surveillance would 
prevent these type of abuses regarding informed consent from taking place. Critics of my 
solution are likely to bring up privacy issues regarding the video surveillance at testing centers. 
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One answer is that video surveillance is already in place in America and many other countries to 
ensure the safety of its citizens, even if it may not ask for their consent. But still, as a solution for 
this problem, the FDA can require informed consent procedures to include a consent that the test 
subjects agree to being video taped and recorded at the testing center. This consent to video 
recording and surveillance will spare the FDA from solving problems arising from privacy 
issues.  
 
VI. CONCLUSION 
 
  Despite  the privacy concerns that may arise in some rare instances, remote video 
surveillance of research testing centers will provide a viable solution to the problem of 
unethical treatment of research test subjects around the world. This is because other 
solutions that have been presented to solve the problem of the unethical treatment of test 
subjects, places upon them the burden to know the existing law, and taking affirmative 
actions to remedy any damages they might have suffered. In contrast, my solution is 
better because it elevates the responsibility of providing ethical treatment to research test 
subjects around the globe. In addition, it solves the monetary problem of the FDA 
inspectors who are unable to conduct inspections of testing centers in America and in 
foreign countries because of the lack of funding. My solution places the monetary burden 
of installing video cameras on the rich pharmaceutical companies, and allows the FDA 
inspectors to inspect the centers remotely from anywhere they desire, without bearing a 
heavy financial burden. Therefore, the FDA should be amended such that pharmaceutical 
 32 
companies are required to place video cameras at testing centers where they would 
conduct their new drug trials.  
 
 
 
